PRESCRIBE AJOVY FOR LONG-ACTING PROTECTION AGAINST MIGRAINE¹*

Available in monthly and quarterly dosing

MONTHLY

AJOVY 225 mg/1.5 mL autoinjector

Sig: 225 mg subcutaneous (1 autoinjector)
every month

Disp: 1.5 mL

Refills: 11

QUARTERLY

AJOVY 225 mg/1.5 mL autoinjector

Sig: 675 mg subcutaneous (3 autoinjector)
every 3 months

Disp: 4.5 mL

Refills: 3

No loading dose

No titration needed

Not made with natural rubber latex

No significant differences in safety or efficacy were observed between monthly and quarterly dosing

Available in a prefilled syringe

Administered at home by the patient or caregiver or in office by a healthcare professional

Studied alone and in combination with oral preventive treatments

Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions.

AJOVY is indicated for the preventive treatment of migraine in adults.

Please see full Prescribing Information for AJOVY.

*“Long-acting” and “lasting protection” defined as reduction in monthly average migraine or headache days measured over a 12-week period following a monthly 225 mg SC dose or quarterly 675 (225 mg x 3) SC dose.¹

SC: subcutaneous.

References: 1. AJOVY® (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc.

PRESCRIBE AJOVY FOR LONG-ACTING PROTECTION AGAINST MIGRAINE1*

PRESCRIBE AJOVY FOR LONG-ACTING PROTECTION AGAINST MIGRAINE¹*